Concepedia

Ernest Nadal-Alforja

EN

3

Publications

686

Citations

3

H-Index

2018

Active since

Affiliations

Institut Català d'Oncologia(Current)

Vall d'Hebron Hospital Universitari

Ernest Nadal-Alforja is an author at Institut Català d'Oncologia specializing in radiation oncology, cancer therapeutics, and oncology.

Top concepts

MedicineOncologyLung CancerCancer TherapyRadiation OncologyHealthMolecular OncologyPathologyRadiologyRadiotherapy

Publications per year

2018–2019

3

Publications

3

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo et al. · Journal of Clinical Oncology · 2018 · 68 citations

Surgical Oncology, Medicine, High Response Rate +12

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.

Solange Peters, Dirk De Ruysscher, Urania Dafni et al. · Journal of Clinical Oncology · 2018 · 24 citations

Concurrent Immune-checkpoint Inhibition, Pharmacotherapy, Immunotherapy +17

Rows per page

1–3 of 3